Ha-ras overexpression mediated cell apoptosis in the presence of 5-fluorouracil

Ya-Shih Tseng1, Ching-Cherng Tzeng, Allen Wen-Hsiang Chiu

  • 1Department of Microbiology and Immunology, National Cheng Kung University, College of Medicine, Tainan, Taiwan.

Insights

Overexpressing the Ha-ras oncogene sensitizes cells to 5-fluorouracil (5-FU) chemotherapy, inducing apoptosis via specific molecular pathways. Targeting these pathways offers new treatment strategies for Ha-ras-related cancers.

Area of Science:

  • Molecular Oncology
  • Cancer Cell Death Mechanisms
  • Chemotherapy Sensitization

Background:

  • The Ha-ras oncogene plays a role in various cancers.
  • 5-fluorouracil (5-FU) is a common chemotherapy agent.
  • Understanding drug sensitivity mechanisms is crucial for effective cancer treatment.

Purpose of the Study:

  • To investigate the relationship between Ha-ras expression and 5-FU sensitivity.
  • To elucidate the molecular pathways involved in 5-FU-induced apoptosis in Ha-ras-overexpressing cells.
  • To explore potential therapeutic strategies for Ha-ras-related cancers.

Main Methods:

  • Utilized a mouse NIH3T3 cell line (7-4) with an inducible Ha-ras oncogene.
  • Assessed 5-FU sensitivity by monitoring apoptosis markers (caspase-3 activation, mitochondrial membrane potential, DNA fragmentation).
  • Investigated the role of various signaling molecules (Ras, Raf-1, PI3K, Rac1, RhoA, Bcl-2) and cell cycle regulators.

Main Results:

  • Increased Ha-ras expression significantly sensitized cells to 5-FU, leading to apoptosis.
  • Inhibition of Ras, Raf-1, PI3K, or Bcl-2 prevented 5-FU-induced apoptosis.
  • Cell cycle perturbations at G1/S and G2/M transitions were observed, linked to altered cyclin E, p21, and Cdc 2 phosphorylation.

Conclusions:

  • Ras, Raf-1, PI3K, and Bcl-2 pathways are critical mediators of 5-FU-induced apoptosis in Ha-ras-overexpressing cells.
  • Cell cycle dysregulation contributes to 5-FU-triggered apoptosis.
  • Findings suggest optimized 5-FU dosing and combination therapies targeting PI3K and Bcl-2 for Ha-ras-related cancers.